NCT06193811View on ClinicalTrials.gov

A Study in Healthy People to Compare Two Different Tablets of BI 685509 and to Test How Food and Esomeprazole Influence the Amount of BI 685509 in the Blood

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 16, 2024

Primary Completion Date

March 14, 2024

Study Completion Date

March 14, 2024

Conditions
Healthy
Interventions
DRUG

Avenciguat (BI 685509) (intended commercial formulation (iCF))

Avenciguat (BI 685509) (intended commercial formulation (iCF))

DRUG

Avenciguat (BI 685509) (trial formulation 2 (TF2))

Avenciguat (BI 685509) (trial formulation 2 (TF2))

DRUG

esomeprazole

esomeprazole (Nexium mups)

Trial Locations (1)

88397

Humanpharmakologisches Zentrum Biberach, Biberach

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY